<div class="headers"><div>Figure 3. Percentage of change from treated baseline (BL) in LDL cholesterol at week 6 in prespeciﬁed subgroups treated with ezetimibe added on to atorvastatin 40 mg versus atorvastatin 80 mg (A80).</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<thead>
<tr>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey;'> </th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>row/col</th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>1(A)</th>
</tr>
</thead>
<tbody>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'>1</td>
<td style='border-bottom: 2px solid grey; text-align: left;'>1</td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p class="">*The 2 substrata with baseline (BL) LDL cholesterol  100 to  130 mg/dl and  130 to  160 mg/dl were combined to make 1 group with BL LDL cholesterol  100 to  160 mg/dl because of small numbers of patients included in the substrata with  130 to  160 mg/dl. †BL HDL cholesterol cutoffs were  40 or  40 mg/dl for men and  50 or  50 mg/dl for women. Bars indicate SE. BMI   body mass index; E   ezetimibe 10 mg; HDL-C   HDL cholesterol; LDL-C   LDL cholesterol; TG   triglycerides</p></td>
</tr>
</tbody>
</table>
